Journal of Clinical Oncology
Articles in this Issue
Bridging the digital literacy gap: Empowering patients and care partners through the Digital Sherpa program.
e13716 Background: Digital literacy is vital for navigating modern healthcare, yet many older patients and care partners, especially in underrepresented c...
A phase 2 basket trial of ado-trastuzumab emtansine for patients with <i>HER2</i> amplified cancers.
3020 Background: The HER2 gene is commonly amplified (amp) across a variety of tumor types. Ado-trastuzumab emtansine (TDM1) is a...
Efficacy and safety of RC48-ADC in triple-negative breast cancer subtypes: FUSCC-TNBC-umbrella trial results.
1109 Background: RC48-ADC is a novel HER2-targeting antibody-drug conjugate. This study evaluated RC48-ADC in pretreated triple-negative breast cancer (TN...
The association of previous cancer history with the incidence of prostate cancer harboring germline mutations.
e17142 Background: Prostate Cancer (PCa) is the most common cancer in men and is the second leading cause of cancer-related mortality in men in the USA. I...
A prospective, single-arm clinical study of icaritin in combination with gemcitabine and nab-pacitaxel in patients with advanced pancreatic ductal adenocarcinoma not received prior systemic therapy.
e16362 Background: Pancreatic cancer is recognized as one of the most lethal malignant neoplasm, with approximately 80% of patients presenting with advanc...
Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab.
e21583 Background: Uveal melanoma (UM) is a rare cancer that often metastasizes to the liver leading to a very poor prognosis. A combination of a one-time...
Primary effusion lymphoma in human immunodeficiency virus (HIV)–negative population: A systematic review and meta-analysis.
e19089 Background: Primary effusion lymphoma (PEL) represents a small proportion of non-Hodgkin lymphomas, historically associated with human immunodefici...
Updated data of efficacy and safety of luvometinib (FCN-159) in pediatric participants with neurofibromatosis type 1 from a multi-center, open-label, single-arm phase 2 study.
10044 Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease characterized by multiple progressive tumor and non-tumor manife...
A phase II study of prophylactic thrombopoietin combined with magnetic resonance guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy and concurrent chemotherapy for thoracic esophageal cancer.
e16116 Background: Previous large phase III trials of preoperative concurrent chemoradiotherapy and definitive chemoradiotherapy (Dt 40-60Gy) in esophagea...
A comprehensive five-year analysis of gastric cancer mortality disparities in the midwest region (2018–2023): Trends, factors, and implication.
e16154 Background: Gastric cancer is a major public health issue, contributing to morbidity and mortality. In the U.S., disparities in gastric cancer mort...
Living beyond cancer: The long-term impact of breast cancer diagnosis on cognitive function.
1633 Background: While some clinical studies report greater cognitive difficulties in middle-aged women diagnosed with and treated for breast cancer over...
Renal cell carcinoma survival in the immunotherapy era: A comprehensive analysis of healthcare and socioeconomic inequalities.
e16528 Background: Use of immunotherapy after surgery and in the metastatic setting has significantly improved overall survival (OS) in patients with rena...
Preferred first-line (1L) treatment for metastatic urothelial carcinoma (mUC) after prior immune checkpoint inhibitor (ICI) therapy: Results from a national survey.
e16570 Background: ICI therapy may be used for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), or as adjuvant or perioperati...
A retrospective study of the efficacy and safety of donafenib combined with TACE as adjuvant therapy in patients with high-risk recurrence factors after hepatocellular carcinoma surgery.
e16300 Background: Adjuvant therapy may have an important role in decreasing recurrence rates and improve survival in selected patients with HCC following...
Results of the prospective randomized controlled trial VOG-01: Neoadjuvant endocrine therapy ribociclib + fulvestrant + GnRH-a versus chemotherapy 4 AC + 4 T for early HR+/HER2-negative breast cancer in premenopausal patients.
606 Background: CDK4/6 inhibitors are used to treat HR+/HER2- metastatic breast cancer in combination with endocrine therapy. However, there is still a la...
Rural-urban disparities in lung cancer screening and outcomes: A comprehensive study of Texas counties.
e13528 Background: Lung cancer is the second most common and the first most deadly cancer in the United States. While lung cancer cases have declined in r...
A phase II (Alliance/A091802) randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC).
6002 Background: There is a need for continued improvement in outcomes with systemic therapy for advanced cSCC. Pre-clinical data suggest immunologic syne...
Real-world effectiveness and safety of RC48-ADC combined with PD-1 inhibitors for patients with metastatic urothelial carcinoma: A retrospective multicenter study.
e16551 Background: RC48 antibody-drug conjugate (ADC) combined with PD-1 inhibitor has significantly impacted the treatment of metastatic urothelial carci...
Clinical phenotypes and management of patients with musculoskeletal immune-related adverse events treated with immune checkpoint inhibitors.
e14625 Background: Immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) can cause systemic toxicities, including musculoskeletal...
Risk factors and outcomes of second primary cancers in colorectal cancer patients by primary tumor site.
e15704 Background: Patients with colorectal cancer (CRC) have an increased risk of developing a second primary cancer (SPC) at any site. Understanding the...
21 years of tonsillar cancer mortality: Trends, disparities, and public health challenges.
e22553 Background: Tonsillar squamous cell carcinoma (SCC), the most common oropharyngeal cancer, has shown increasing mortality trends despite declining...
Association of polycythemia vera treatments with reduced mortality rates among US veterans.
e23298 Background: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by excessive red blood cell production due to genetic mutations,...
Outcomes with non-BCMA CAR T cell therapy for multiple myeloma: A systematic review and meta-analysis.
e19541 Background: Chimeric antigen receptor T cell therapy (CAR-T) has shown promise in treating multiple myeloma. Anti-BCMA CAR T cell therapy for MM ha...
Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE CANCER 1).
3015 Background: Rare tumors constitute a heterogeneous group of cancers with limited treatment options and poor outcomes. To address the need for novel t...
Operational feasibility and impact of a digital platform for symptom management in oncology: A real-world healthcare provider perspective.
e13724 Background: Digital health technologies are emerging as valuable tools for enhancing patient monitoring, improving operational efficiency, and deli...